Pre-transplant Panel Reactive Antibody and Survival in Adult Cystic Fibrosis Patients After Lung Transplantation.

Abstract

Survival implications of pre-transplant antibodies to human leukocyte antigens prior to lung transplantation (LTx) in adult cystic fibrosis (CF) patients are unknown. Data from the United Network for Organ Sharing Registry (1987-2013) were used to compare survival differences in adult CF patients with pre-transplant class I and II panel reactive antibody (PRA) levels ≤10 versus >10%. Of 3149 CF LTx recipients, 1526 and 1399 were included in univariate survival analyses of class I and II PRA, respectively, while 1106 and 1001 were included in multivariate Cox analyses for class I and class II, respectively. Kaplan-Meier survival functions failed to demonstrate significant differences in survival with PRA >10% for class I (Log-rank test: χ (2) (df=1): 1.11, p=0.293) or class II (Log-rank test: χ (2) (df=1): 0.99, p=0.320). Adjusting for covariates, multivariate Cox models demonstrated that class II PRA >10% was associated with a significant increase in mortality hazard (HR 1.918; 95% CI 1.128, 3.261; p=0.016), whereas class I PRA >10% was uncorrelated with this outcome. Pre-transplant PRA class II >10% in adult CF patients is associated with elevated mortality hazard after LTx.